Contribution of Dolutegravir to Obesity and Cardiovascular Disease


The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir based regimen on on lipid and metabolic profiles, renal function, body composition, vascular function and diet.

Full Title of Study: “Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2021

Detailed Description

Over the last decades, the use of combined antiretroviral therapy has led to profound suppression of HIV-1 replication and increased the survival of persons living with HIV (PLWH) to close to that of the general population. As a consequence, the spectrum of diseases related to HIV has shifted from opportunistic AIDS-related diseases towards long-term-age-related complications. Individuals living with HIV are now exhibiting accelerated development of obesity, metabolic derangements and cardiovascular disease (CVD). Recent compelling clinical evidence has documented a drastic shift in anthropometric profiles among persons living with HIV. In addition, several reports present dolutegravir, a second-generation integrase inhibitor currently highly prescribed for its high antiviral efficiency, as the potential cause of unpredicted weight gain. A critical gap in the investigators' knowledge is a lack of understanding of the etiopathology of the contribution of dolutegravir on weight gain and the consequential impact on obesity and cardiovascular disease in persons living with HIV on combined antiretroviral therapy. As overweight and obesity are among the leading risk factors for cardiovascular disease in persons living with HIV, it is critical to directly investigate whether dolutegravir increases fat mass in persons living with HIV and whether body weight gains-associated with dolutegravir based regimen contribute to the increased prevalence of CVD in this population of people.

This application seeks to investigate alterations in body fat and cardiometabolic risk markers associated with dolutegravir. The investigators propose that in patients with undetectable plasma HIV RNA, there is a direct correlation of weight gain and dolutegravir after antiretroviral regimen switch. They also contend that dolutegravir associated weight gain induces a phenotypic metabolic shift which alters the vascular endothelium and potentiates CVD risk. If the investigators are correct in their hypotheses, modifications in the clinical practice of treatment and prevention strategies for CVD in people living with HIV may be warranted.

Herein the investigators propose a novel translational study which will concomitantly investigate in human patients and animal models of HIV:

1. whether dolutegravir based regimen increases body weight

2. the mechanisms whereby dolutegravir increases body weight

3. whether dolutegravir-mediated body weight gain increases the risk for CVD in PLWH.


  • Drug: Dolutegravir 50 MG
    • 15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
  • Drug: Antiretroviral/Anti HIV
    • 15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.

Arms, Groups and Cohorts

  • Active Comparator: Switch from a non-integrase based regimen to dolutegravir
    • Participants with HIV-1 infection who have had viral suppression on a non-integrase based antiretroviral regimen for greater than or equal to 3 months will be switched to a dolutegravir based regimen dosed at 50 milligrams (MG) once daily. Background regimen will remain the same.
  • Active Comparator: Continue on non-integrase inhibitor based regimen
    • Participants not currently on an integrase based regimen who remain on current suppressive therapy will remain on current antiretroviral regimen.

Clinical Trial Outcome Measures

Primary Measures

  • Change in Weight
    • Time Frame: 24 weeks
    • Change from baseline kilograms (kg) of weight at 24 weeks

Secondary Measures

  • Change in body mass index (BMI)
    • Time Frame: 24 weeks
    • Total change in body mass index -height and weight will be combined to report BMI (Kilogram/Height in centimeters^2)
  • Change in vascular endothelial function
    • Time Frame: 24 weeks
    • Change from baseline vessel diameter (millimeters) at 24 weeks
  • Height
    • Time Frame: 24 weeks
    • Measurement of height (centimeters) from baseline to 24 weeks

Participating in This Clinical Trial

Inclusion Criteria

Subjects must meet the following criteria to be eligible for participation in this study:

  • Age greater than or equal to 18 years with HIV-1 who have been virologically suppressed (HIV-1 RNA < 50 copies for greater than or equal to 3 months on a non-integrase strand transfer inhibitor-based regimen
  • Have the ability to understand and sign an informed consent written in the English language

Exclusion Criteria

Subjects meeting any of the following exclusion criteria are not to be enrolled in this study:

  • Age less than 18 years without HIV-1 infection
  • Has hypersensitivity or other contraindication to any of the components of the study
  • Has active diagnosis of untreated hepatitis due to any cause
  • Has a history or current evidence of any condition, laboratory abnormality or other circumstance ( including drug or alcohol use or dependence) that might confound the results of the study or interfere with the subject's participation for the full duration of the study
  • Is taking or is anticipated to require long term systemic immunosuppressive therapy, immune modulators, or any prohibited therapies from 60 days prior to Screening/Day 1 visit through to the end of study
  • Has documented or suspected dolutegravir-associated resistance mutations specifically:

Q148H/K/R/N in combination with E138K or G1402/A or N155H.

  • Has a life expectancy less than or equal to one year
  • Is pregnant, breastfeeding, or expecting to donate eggs or sperm or conceive or father a child at any time during the study and 6 weeks following the end of study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Augusta University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jonell Poe, Assistant Clinical Professor, Physician Assistant – Augusta University
  • Overall Official(s)
    • Jonell B Poe, MPAS, Principal Investigator, Augusta University
  • Overall Contact(s)
    • Ivy Tillman, 706-721-1379,

Citations Reporting on Results

Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013 Nov;52(11):981-94. doi: 10.1007/s40262-013-0093-2. Review.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.